Vir Historical Income Statement
| VIR Stock | USD 7.86 0.24 3.15% |
Historical analysis of Vir Biotechnology income statement accounts such as Net Interest Income of 86.5 M, Interest Income of 86.5 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 20.4 M can show how well Vir Biotechnology performed in making a profits. Evaluating Vir Biotechnology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vir Biotechnology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Vir Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vir Biotechnology is a good buy for the upcoming year.
Vir |
About Vir Income Statement Analysis
Vir Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vir Biotechnology shareholders. The income statement also shows Vir investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Vir Biotechnology Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Vir Biotechnology generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vir Biotechnology. It is also known as Vir Biotechnology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Vir Biotechnology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vir Biotechnology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vir Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.At this time, Vir Biotechnology's Net Income Applicable To Common Shares is relatively stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 439K | 28.1M | 82.4M | 86.5M | Net Interest Income | 439K | 28.1M | 82.4M | 86.5M |
Vir Biotechnology income statement Correlations
Click cells to compare fundamentals
Vir Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vir Biotechnology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Tax Provision | 154K | 54K | 21.2M | 238.4M | (58.3M) | (55.4M) | |
| Net Interest Income | 8.5M | 2.8M | 439K | 28.1M | 82.4M | 86.5M | |
| Interest Income | 8.5M | 2.8M | 439K | 28.1M | 82.4M | 86.5M | |
| Depreciation And Amortization | 4.5M | 5.4M | 12.0M | 15.5M | 19.5M | 20.4M | |
| Interest Expense | 8.0M | 3.8M | 272.9M | 183.1M | 210.6M | 221.1M | |
| Selling General Administrative | 37.6M | 70.9M | 160.8M | 161.8M | 173.7M | 103.0M | |
| Total Revenue | 711K | 76.4M | 1.1B | 1.6B | 86.2M | 81.9M | |
| Gross Profit | 711K | 76.4M | 1.0B | 1.4B | 83.4M | 79.2M | |
| Other Operating Expenses | 178.7M | 373.3M | 666.3M | 747.4M | 770.5M | 461.6M | |
| Operating Income | (178.0M) | (297.0M) | 276.9M | 833.1M | (684.3M) | (650.1M) | |
| Net Income From Continuing Ops | (174.7M) | (298.7M) | 528.6M | 515.8M | (600.7M) | (570.7M) | |
| Ebit | (178.0M) | (298.7M) | 408.8M | 817.6M | (684.3M) | (650.1M) | |
| Research Development | 148.5M | 302.4M | 448.0M | 474.6M | 589.7M | 334.1M | |
| Ebitda | (173.5M) | 514.3M | 420.8M | 833.1M | (664.9M) | (631.6M) | |
| Cost Of Revenue | 143.1M | 301.6M | 65.9M | 146.3M | 2.8M | 2.6M | |
| Total Operating Expenses | 178.7M | 373.3M | 600.5M | 601.1M | 767.7M | 427.8M | |
| Reconciled Depreciation | 4.5M | 5.4M | 5.8M | 6.8M | 16.9M | 17.8M | |
| Income Before Tax | (174.5M) | (298.6M) | 549.8M | 754.3M | (628.2M) | (596.8M) | |
| Total Other Income Expense Net | 3.5M | 296.7M | 129.1M | (78.8M) | 56.1M | 63.9M | |
| Net Income Applicable To Common Shares | (174.7M) | (298.7M) | 528.6M | 515.8M | 593.2M | 622.9M | |
| Net Income | (174.7M) | (298.7M) | 528.6M | 515.8M | (615.1M) | (584.3M) | |
| Income Tax Expense | 154K | (54K) | 21.2M | 238.4M | (13.1M) | (12.4M) |
Pair Trading with Vir Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against Vir Stock
The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.